Altered TRPM3-Dependent Cytosolic and Mitochondrial Calcium Influx in Natural Killer Cells of Post-COVID-19 Condition Patients.

ingentiumby ingentium

In Long Covid Literature.

Publication date: Jul 01, 2026

According to the World Health Organization (WHO), approximately 6% of COVID-19 cases develop serious long-term sequelae referred to as post-COVID-19 condition (PCC). Immunological disturbances such as persistent activation of immune cells and reduced cytotoxicity by natural killer (NK) cells are reported as key aspects in PCC. Recently, electrophysiological studies by our group demonstrated impairment of transient receptor potential melastatin 3 (TRPM3) ion channels in NK cells from PCC patients. The significant reduction in TRPM3 channel function and reduced functional activity by NK cells warrants further investigation. Hence, using live cell calcium (Ca) imaging ex vivo, we examined the downstream impact of TRPM3 ion channel dysfunction on intracellular and mitochondrial Ca mobilization in NK cells from N = 8 PCC patients, age and sex matched to N = 8 PCC healthy controls (HC). Our findings provide new evidence of altered passive and TRPM3-mediated Ca influx, significantly impacting cytoplasmic and mitochondrial Ca mobilization in PCC. Passive cytosolic Ca influx amplitude (p

Open Access PDF

Concepts Keywords
Calcium Adult
Downstream Aged
Immunological Calcium
Live Calcium
Mitochondrial Calcium Signaling
calcium signalling
COVID-19
Cytosol
Female
Humans
Killer Cells, Natural
Male
Middle Aged
Mitochondria
mitochondria
natural killer cells
Post-Acute COVID-19 Syndrome
post‐COVID‐19 condition
Pregnenolone
Pregnenolone
pregnenolone sulfate
SARS-CoV-2
TRP channels
TRPM Cation Channels
TRPM Cation Channels
TRPM3
TRPM3 protein, human

Semantics

Type Source Name
drug DRUGBANK Calcium
disease MESH COVID-19
drug DRUGBANK Factor IX Complex (Human)
disease MESH PCC
drug DRUGBANK Pregnenolone
pathway REACTOME Immune System
disease MESH Long Covid
disease MESH Infection
drug DRUGBANK Gold
disease MESH Myalgic Encephalomyelitis
pathway REACTOME TRP channels
drug DRUGBANK ATP
disease MESH CaM
pathway REACTOME Release
drug DRUGBANK MCC
disease MESH severe acute respiratory syndrome
drug DRUGBANK L-Tryptophan
pathway REACTOME Reproduction
disease MESH ARS
disease MESH fatigue
disease MESH myalgia
pathway REACTOME Innate Immune System
disease MESH viral infections
pathway REACTOME Metabolism
pathway REACTOME Muscle contraction
disease MESH death
disease MESH encephalomyelitis
disease MESH neuropathic pain
disease MESH neurodegenerative diseases
pathway REACTOME Neurodegenerative Diseases
disease MESH cancer
disease MESH channelopathies
disease MESH pain
drug DRUGBANK Sulfate ion
disease MESH alcohol abuse
disease MESH chronic illness
disease MESH cardiovascular disease
disease MESH metabolic syndrome
disease MESH insomnia
drug DRUGBANK Edetic Acid
disease MESH Rad
disease MESH APC
drug DRUGBANK Water
drug DRUGBANK Sodium Chloride
drug DRUGBANK Potassium Chloride
drug DRUGBANK Magnesium chloride
disease MESH glass
disease MESH ash
drug DRUGBANK Calcium Chloride
drug DRUGBANK Dextrose unspecified form
disease MESH ito
pathway REACTOME Mitochondrial Uncoupling
disease MESH Image
drug DRUGBANK Cysteamine
drug DRUGBANK Dimethyl sulfoxide
disease MESH IBM
disease MESH included
drug DRUGBANK Methionine
disease MESH dehydration
disease MESH fibrosarcoma
disease MESH Alzheimer’s disease
disease MESH myopathies
drug DRUGBANK Isoxaflutole
disease MESH ics
drug DRUGBANK Oxygen
drug DRUGBANK Roflumilast
disease MESH Mrs
disease MESH CHIME
disease MESH Infectious Diseases
disease MESH Fac
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH Inflammation
disease MESH Cachexia
disease MESH Sarcopenia
disease MESH Syndrome
disease MESH Kidney Disease
disease MESH Eye Disease
disease MESH Intellectual Disability
disease MESH Epilepsy
drug DRUGBANK Zinc
drug DRUGBANK Naltrexone
pathway REACTOME Signal Transduction
drug DRUGBANK Nerve Growth Factor
disease MESH Low Back Pain

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *